Barclays PLC Boosts Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Barclays PLC lifted its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 394.5% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 36,577 shares of the medical instruments supplier's stock after buying an additional 29,180 shares during the period. Barclays PLC owned approximately 0.16% of LeMaitre Vascular worth $3,396,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. NBC Securities Inc. grew its holdings in shares of LeMaitre Vascular by 73.2% during the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier's stock valued at $40,000 after buying an additional 183 shares during the last quarter. USA Financial Formulas acquired a new position in LeMaitre Vascular during the third quarter valued at $60,000. GAMMA Investing LLC boosted its stake in shares of LeMaitre Vascular by 34.3% in the third quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier's stock worth $68,000 after buying an additional 188 shares during the last quarter. nVerses Capital LLC boosted its position in LeMaitre Vascular by 33.3% in the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier's stock worth $66,000 after purchasing an additional 200 shares in the last quarter. Finally, Van ECK Associates Corp acquired a new stake in shares of LeMaitre Vascular during the 2nd quarter worth approximately $75,000. 84.64% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the firm's stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the transaction, the director now directly owns 2,278 shares of the company's stock, valued at $231,148.66. This trade represents a 62.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 10.79% of the stock is currently owned by company insiders.

LeMaitre Vascular Price Performance

LMAT stock traded up $1.25 during trading on Tuesday, hitting $92.63. The stock had a trading volume of 55,647 shares, compared to its average volume of 131,401. The company's 50-day moving average price is $97.74 and its two-hundred day moving average price is $90.16. LeMaitre Vascular, Inc. has a twelve month low of $52.88 and a twelve month high of $109.58. The stock has a market capitalization of $2.08 billion, a P/E ratio of 50.62, a PEG ratio of 2.47 and a beta of 0.93.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The firm had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. During the same period in the previous year, the company posted $0.33 earnings per share. The business's revenue was up 15.6% on a year-over-year basis. As a group, sell-side analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, December 5th. Stockholders of record on Thursday, November 21st were paid a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 0.69%. The ex-dividend date was Thursday, November 21st. LeMaitre Vascular's dividend payout ratio is currently 34.97%.

Wall Street Analyst Weigh In

Several research firms recently issued reports on LMAT. StockNews.com cut shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a research note on Friday, December 13th. Cantor Fitzgerald began coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They issued a "neutral" rating and a $96.00 price objective for the company. Oppenheimer restated an "outperform" rating and set a $93.00 target price (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Finally, Barrington Research lifted their price target on LeMaitre Vascular from $92.00 to $93.00 and gave the company an "outperform" rating in a research note on Friday, November 1st. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, LeMaitre Vascular has an average rating of "Moderate Buy" and a consensus target price of $94.57.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.